T-E Pharma’s subsidiary, Immunwork, Inc., recently announced that the latest research findings on its next-generation long-acting octreotide analog TE-8214 have
T-E Meds supported YmmunoBio in the development of an MMAF/Exatecan dual-payload ADC, which was recently incorporated into a novel ADC
International technology and health media Tech Times recently featured Immunwork’s long-acting GLP-1 receptor agonist TE-8105, highlighting its First-in-Human clinical results
First-in-Human Clinical Results Published in The Journal of Clinical Pharmacology and Presented at WCP2026 T-E Pharma’s subsidiary, Immunwork, Inc., announced
We’re excited to announce that Dr. Art Hsing-Mao Chu, CEO of T-E PHARMA, will be presenting at the Investment Summit
“The development of TE-1182, an ADC for the treatment of HER2-resistant tumors” was selected as a significant case of the
T-E Pharma is honored to be invited by the Journal of the Chinese Chemical Society (JCCS) to publish a review
T-E Pharma has officially launched its pre-initial public offering (pre-IPO) fundraising program. The proceeds will be used to accelerate the
Great news! The long-acting GLP-1 receptor agonist TE-8105 has achieved an innovative breakthrough in formulation development, successfully creating a more
We are honored to announce that Dr. Tse-Wen Chang, Chairman of T-E Pharma, and Dr. Hsin-Mao Chu, CEO of the
